{"nctId":"NCT01197417","briefTitle":"Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis","startDateStruct":{"date":"2010-12"},"conditions":["Sickle Cell Disease"],"count":208,"armGroups":[{"label":"Magnesium group","type":"EXPERIMENTAL","interventionNames":["Drug: Intravenous Magnesium Sulfate"]},{"label":"Placebo group","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Normal Saline Placebo"]}],"interventions":[{"name":"Intravenous Magnesium Sulfate","otherNames":[]},{"name":"Normal Saline Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* age 4-21 years, inclusive\n* Sickle cell anemia (Hb SS) or Sickle beta zero thalassemia disease (Hb Sβ°)\n* failed intravenous opioid pain management in the emergency department prior to the decision to admit the patient\n* admitted to the inpatient unit for sickle cell pain crisis\n\nExclusion Criteria:\n\n* patient received more than 12 hours of intravenous pain medication prior to enrollment\n* previous enrollment in this study (only one admission per child is eligible)\n* history of allergy/intolerance to both intravenous morphine and hydromorphone\n* known other cause for pain (avascular necrosis, gall bladder disease, priapism, etc.)\n* patient with greater than 10 admissions for pain crisis in the past year\n* patient maintained on daily opioids or chronic transfusions for chronic sickle cell pain\n* transfusion within the previous two months\n* known kidney or liver failure (elevation of liver function tests does not warrant exclusion)\n* known pulmonary hypertension\n* pregnancy\n* diagnosis of bacterial infection, fever ≥39.5°C, acute chest syndrome, hemodynamic instability or sepsis\n* current oral magnesium supplementation or current enrollment in another therapeutic study protocol\n* previously diagnosed clinical stroke\n* current or planned use of neuromuscular blocker, nifedipine, ritodrine, or terbutaline\n* allergy to magnesium sulfate\n* discharge from an inpatient unit within 72 hours of arrival in the emergency department for the current pain crisis","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hospital Length of Stay (Hours)","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Morphine Equivalents Per Kilogram of Body Weight Used During Hospitalization","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":null},{"groupId":"OG001","value":"1.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Hypotension Associated With Infusion","description":"For each study drug infusion, systolic blood pressure (SBP) was measured just prior to the start of the infusion and again every 10 minutes until 30 minutes until the end of the infusion. Hypotension was defined as a greater than 20% reduction in SBP relative to corresponding baseline measurement for any study drug infusion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Warm Sensation Associated With Study Drug Infusion","description":"Patient spontaneously reported feelings of warmth during any study drug infusion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Rehospitalization","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Development of Acute Chest Syndrome (ACS)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospital Length of Stay","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":null},{"groupId":"OG001","value":"60.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":101},"commonTop":["Fever","Nausea","Headache","Oxygen saturation decreased","Itching"]}}}